Other News To Note
Monday, December 5, 2011
Northwest Biotherapeutics Inc., of Bethesda, Md., said it implemented a restructuring to reduce its liabilities from $48 million to $16.5 million, removing $31.5 million through settlement, retirement and conversion. The firm said the move will strengthen its balance sheet as it accelerates its 240-patient Phase II trial of its lead dendritic cell-based vaccine in glioblastoma multiforme. Northwest also recently received clearance for a Phase III trial in prostate cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.